Klotho Neurosciences, Inc. (KLTO)
NASDAQ: KLTO · Real-Time Price · USD
0.340
-0.008 (-2.27%)
At close: Nov 20, 2024, 4:00 PM
0.330
-0.010 (-2.91%)
After-hours: Nov 20, 2024, 6:24 PM EST
Company Description
Klotho Neurosciences, Inc., a biopharmaceutical company, develops therapies for neurological and age-related disorders, and specialty diagnostics.
Its products include cell and gene therapies to mitigate age-related pathologies, such as dementia symptoms, and Alzheimer and neuromuscular diseases; biologics/biosimilars in the treatment of cancer; and melanocortin receptors.
The company has a strategic partnership with Japan’s Okinawa Research Center for the research and development of Klotho gene therapy in enhancing longevity and reducing age-related diseases.
The company was formerly known as Anew Medical, Inc. and changed its name to Klotho Neurosciences, Inc. in September 2024.
Klotho Neurosciences, Inc. is based in Omaha, Nebraska.
Klotho Neurosciences, Inc.
| Country | United States |
| Founded | 2019 |
| Industry | Biotechnology |
| Sector | Healthcare |
| CEO | Joseph Sinkule |
Contact Details
Address: 13576 Walnut Street, Suite A Omaha, Nebraska 68144 United States | |
| Phone | 833 931 6330 |
| Website | klothoneuro.com |
Stock Details
| Ticker Symbol | KLTO |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001907223 |
| ISIN Number | US49876K1034 |
| Employer ID | 86-2727441 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Dr. Joseph Sinkule Pharm.D. | Founder, Chief Executive Officer, Chairman of the Board and Secretary |
| Peter J. Moriarty | Chief Operating Officer |
| Dr. Shalom Z. Hirschman M.D. | Medical Advisor and Director |
| Jeffrey LeBlanc | Chief Financial Officer |
| Dr. Miguel Chillon Rodriguez | Chief Scientific Officer and Consultant |
| Dr. Bradford A. Navia M.D., Ph.D. | Chief Medical Advisor |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Nov 19, 2024 | 10-Q | Quarterly Report |
| Nov 13, 2024 | NT 10-Q | Notification of inability to timely file Form 10-Q or 10-QSB |
| Nov 13, 2024 | 8-K | Current Report |
| Oct 31, 2024 | 8-K | Current Report |
| Oct 31, 2024 | 8-K | Current Report |
| Oct 21, 2024 | 8-K | Current Report |
| Oct 2, 2024 | 8-K | Current Report |
| Oct 1, 2024 | 424B3 | Prospectus |
| Sep 18, 2024 | EFFECT | Notice of Effectiveness |
| Sep 13, 2024 | S-1/A | [Amend] General form for registration of securities under the Securities Act of 1933 |